dc.contributor.author | de Silva, H.J. | en_US |
dc.contributor.author | Wijewickrema, R. | en_US |
dc.contributor.author | Senanayake, N. | en_US |
dc.date.accessioned | 2014-10-29T09:10:26Z | |
dc.date.available | 2014-10-29T09:10:26Z | |
dc.date.issued | 1992 | en_US |
dc.identifier.citation | Lancet. 1992; 339(8802): pp.1136-1138 | en_US |
dc.identifier.issn | 0140-6736 (Print) | en_US |
dc.identifier.issn | 1474-547X (Electronic) | en_US |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/1160 | |
dc.description | Indexed in MEDLINE | |
dc.description.abstract | Acute organophosphorus (OP) poisoning is usually treated with atropine plus cholinesterase reactivators such as oximes, but controlled trials to assess the efficacy of oximes in OP poisoning have not been done. A period when the acetyl cholinesterase reactivator pralidoxime chloride was not available in Sri Lanka gave us the opportunity to compare atropine alone for treatment of moderate to severe OP poisoning (21 patients) with atropine plus pralixodime (24 patients). Outcome, as assessed clinically, was similar in the two groups. These results cast doubt on the necessity of cholinesterase reactivators for treatment of acute OP poisoning. | en_US |
dc.publisher | Lancet Publishing Group | en_US |
dc.subject | Poisoning | |
dc.subject | Poisoning-drug therapy | |
dc.subject | Poisoning-epidemiology | |
dc.subject | Poisoning-mortality | |
dc.subject | Organophosphate Poisoning | |
dc.subject | Atropine-therapeutic use | |
dc.subject | Cholinesterase Reactivators-therapeutic use | |
dc.subject | Pralidoxime Compounds-therapeutic use | |
dc.subject | Clinical Trial | |
dc.subject | Controlled Clinical Trial | |
dc.subject | Sri Lanka-epidemiology | |
dc.title | Does pralidoxime affect outcome of management in acute organophosphorus poisoning? | en_US |
dc.type | Article | en_US |
dc.identifier.department | Medicine | en_US |
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |